A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group (PAES-LTFU)

A Prospective, Post-authorisation Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation, Including a Non-comparative Concurrent Reference Cohort

A prospective, post-authorisation long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort.

Study Overview

• Status: Recruiting
• Conditions: Long Term Efficacy and Safety
• Intervention / Treatment: Drug: Imlifidase administered in the 20-HMedIdeS-19 (PAES) study; Other: Best available treatment administered in the 20-HMedIdeS-19 (PAES) study

Detailed Description

This is a long-term follow-up trial to the post-authorisation efficacy and safety (PAES) trial (trial 20-HMedIdeS-19). The trial will include patients who participated in the PAES trial and were transplanted with a new kidney after treatment with imlifidase (trial drug) or standard of care medication. Imlifidase is a medicine used to prevent the body from rejecting a newly transplanted kidney and is used before transplantation in adults who have antibodies against the donor kidney and are considered 'highly sensitised' based on a positive crossmatch test.

The purpose of this follow-up trial is to fulfil requirements from the European Medicines Agency (EMA) to continue to evaluate efficacy (kidney function) and safety (side effects) over time, for the patients who were transplanted with a new kidney in the PAES trial. The patients will be followed for up to 5 years after transplantation in the PAES trial to collect valuable long-term data.

• Study Type: Interventional
• Enrollment (Estimated): 150
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Central Contact; Phone Number: +46 46 16 56 70; Email: clinicalstudyinfo@hansabiopharma.com

Study Locations

• Czechia
  • Prague, Czechia, 140-21
    • Recruiting
    • Nephrology Clinic Vídeňská 1958/9
    • Principal Investigator: Ondrej Viklický, MD
    • Contact: Ondrej Viklický, MD; Email: ondrej.viklicky@ikem.cz
• Spain
  • Barcelona, Spain, 08035
    • Recruiting
    • Hospital Universitario del Vall d´Hebron
    • Contact: O Bestard, MD; Email: oriol.bestard@vallhebron.cat
    • Principal Investigator: O Bestrad
  • Barcelona, Spain, 08036
    • Recruiting
    • Unidad de Trasplante Renal
    • Contact: F Diekmann, MD; Email: fdiekman@clinic.cat
    • Principal Investigator: F Diekmann, MD
  • Madrid, Spain, 28041
    • Recruiting
    • Hospital Universitario 12 de Octubre
    • Contact: Amado Andres, MD; Email: amado.andres@salud.madrid.org
    • Principal Investigator: Amado Andres

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Signed Informed Consent obtained before any trial-related procedures
• Willingness and ability to comply with the protocol
• Previously transplanted in the clinical trial 20-HmedIdeS-19 (PAES)

Exclusion Criteria:

• Inability by the judgment of the investigator to participate in the trial for other reasons

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Imlifidase; Imlifidase administered in the 20-HMedIdeS-19 (PAES) study	Drug: Imlifidase administered in the 20-HMedIdeS-19 (PAES) study; Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.; Other Names: IdeS; HMED-IdeS; Idefirix
Experimental: Non-Comparative Concurrent Reference Cohort; Best available treatment administered in the 20-HMedIdeS-19 (PAES) study	Other: Best available treatment administered in the 20-HMedIdeS-19 (PAES) study; Normal transplantation routine Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Graft failure-free survival (%) up to 5 years after imlifidase enabled transplantation (imlifidase cohort only)	Graft failure is defined as permanent return to dialysis for at least 6 weeks, re-transplantation, or nephrectomy. Patients not undergoing transplantation will be censored at time zero (i.e. at entry into the PAES trial). Transplanted patients not having an event (graft failure or death) will be censored at the last known date being alive and having a functioning graft. The 5-year graft failure-free survival rates will be estimated using the Kaplan-Meier estimator. Time from enrolment to the first of death or graft failure will be used as time variable.	5-years after transplantation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Graft failure-free survival (%) up to 5 years after transplantation (non-comparative concurrent reference cohort only)	Graft failure is defined as permanent return to dialysis for at least 6 weeks, re-transplantation, or nephrectomy. Patients not undergoing transplantation will be censored at time zero (i.e. at entry into the PAES trial). Transplanted patients not having an event (graft failure or death) will be censored at the last known date being alive and having a functioning graft. The 5-year graft failure-free survival rates will be estimated using the Kaplan-Meier estimator. Time from enrolment to the first of death or graft failure will be used as time variable.	5-years after transplantation
Graft failure-free survival (%) up to 2 and 3 years after transplantation	Graft failure is defined as permanent return to dialysis for at least 6 weeks, re-transplantation, or nephrectomy. Patients not undergoing transplantation will be censored at time zero (i.e. at entry into the PAES trial). Transplanted patients not having an event (graft failure or death) will be censored at the last known date being alive and having a functioning graft. The 2 and 3-year graft failure-free survival rates will be estimated using the Kaplan-Meier estimator. Time from enrolment to the first of death or graft failure will be used as time variable.	2 and 3-years after transplantation
Renal function as evaluated by estimated Glomerular Filtration Rate (eGFR) and serum/plasma creatinine levels	Kidney function assessed by eGFR and serum/plasma creatinine will be summarised over 5 years for the imlifidase group and the reference cohort. eGFR is a measure of kidney function. The serum/plasma creatinine levels will be analysed and eGFR will be calculated according to the modification of diet in renal disease (MDRD) equation. Reduced kidney function is characterised by a decreased eGFR value. For patients in the imlifidase group who are not successfully transplanted, or for any enrolled patients without a functioning graft, their eGFR values will be set to 0 mL/min.	2, 3, and 5-years after transplantation
Patient survival (%) after transplantation	Patient survival up to 2, 3 and 5 years, respectively, will be assessed for the imlifidase group and the reference cohort. The 2, 3, and 5-year patient survival rates will be extracted from Kaplan-Meier curves.	2, 3, and 5-years after transplantation
Graft survival (%) after transplantation	Graft survival up to 2, 3 and 5 years, respectively, will be assessed for the imlifidase group and the reference cohort. Graft survival will be presented with Kaplan-Meier curves. Graft failure is defined as permanent return to dialysis for at least 6 weeks, re-transplantation, or nephrectomy. Patients who die will be censored at time of death.	2, 3, and 5-years after transplantation
Human Leukocyte Antigen (HLA)/Donor Specific Antibodies (DSA) levels (imlifidase cohort only)	HLA antibodies will be analysed using an IgG single antigen solid-phase immunoassay for class I and class II (SAB-HLA). Donor specific antibodies (DSAs) are identified by using the human leukocyte antigen (HLA) profile data from the donor and the recipient to identify HLA-mismatches. The mean fluorescence intensity (MFI) will be summarized for all DSAs with an MFI of ≥1000 at any time during the trial (or the PAES trial).	2, 3, and 5-years after transplantation
Anti-drug antibody (ADA) levels (imlifidase cohort only)	Determination of anti-imlifidase IgG (ADA) concentration in serum will be performed centrally using a customised ImmunoCAP to evaluate imlifidase long-term immunogenicity.	2, 3, and 5-years after transplantation
Proportion of patients (%) with biopsy- and serology (DSA)-confirmed Antibody Mediated Rejections (AMRs)	For-cause biopsies will be obtained to confirm diagnosis for suspected AMRs in both treatment arms. The biopsies will be analysed locally and centrally and evaluated according to Banff criteria version 2017 or later.	2, 3, and 5-years after transplantation
Proportion of patients (%) with biopsy confirmed Cell-Mediated Rejections (CMRs)	For-cause biopsies will be obtained to confirm diagnosis for suspected CMRs in both treatment arms. The biopsies will be analysed locally and centrally and evaluated according to Banff criteria version 2017 or later.	2, 3, and 5-years after transplantation
Treatment of graft rejections	The number of graft rejection episodes treated with dialysis will be recorded	2, 3, and 5-years after transplantation
Treatment of graft rejection	The number of graft rejection episodes treated with plasmapheresis will be recorded	2, 3, and 5-years after transplantation
Treatment of graft rejection	The number of graft rejection episodes treated with medication will be recorded	2, 3, and 5-years after transplantation
Adverse events (AEs)/serious adverse events (SAEs) suspected to be related to imlifidase treatment (imlifidase cohort only)	AEs/SAEs suspected to be related to imlifidase treatment in the PAES trial will be recorded from the time of signed informed consent for participation in the trial until the last trial visit.	2, 3, and 5-years after transplantation
Use of immunosuppressive medication	The patient's use of immunosuppressive medications will be recorded for both cohorts from the time of signed informed consent for participation in the trial until the last trial visit.	2, 3, and 5-years after transplantation
Comorbidities	Information about comorbidities that are medically relevant and registered in the patient' medical record will be collected. Medically relevant comorbidities are infections, malignancy, diabetes mellitus and cardiovascular events.	2, 3, and 5-years after transplantation
Change in patient reported life participation	The Patient-Reported Outcomes Measurement Information System (PROMIS) Social Health domain "Ability to participate in social roles & activities, PROMIS-SF-8a" will be used as a measure of the patients' health related quality of life. The questionnaire includes 8 questions about a persons ability to participate in different social activities and there are 5 different answers to choose from for each question: Never/Rarely/Sometimes/Usually/Always	2, 3, and 5-years after transplantation

Collaborators and Investigators

• Sponsor: Hansa Biopharma AB
• Investigators: Study Director: Clinical Operations, Hansa Biopharma AB

Study record dates

Study Major Dates

• Study Start (Actual): July 3, 2023
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2028

Study Registration Dates

• First Submitted: June 13, 2023
• First Submitted That Met QC Criteria: June 30, 2023
• First Posted (Actual): July 10, 2023

Study Record Updates

• Last Update Posted (Actual): March 7, 2024
• Last Update Submitted That Met QC Criteria: March 6, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Kidney transplantation; Renal transplantation
• Other Study ID Numbers: 20-HMedIdeS-20

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No